Eisai

Bristol Myers culls cell therapy deals with 2 biotechs

BMS has terminated cell therapy pacts with two biotechs amid "portfolio prioritization efforts” within the pharma, one of the affected companies said.

Gabrielle Masson Dec 16, 2024 11:19am

Brain and money connected by a thread on a white background

Eisai pays $46M for Japan rights to Newron's schizophrenia med

Dec 13, 2024 8:37am

Manila folder with CONFIDENTIAL printed on it in red

Alzheimer's trials withheld brain injury risk disclosures: NYT

Oct 24, 2024 11:33am

Eisai plants molecular glue SEED with $1.5B biobucks deal

Aug 6, 2024 10:24am

Eisai adopts Medidata's new clinical trial platform

Jul 25, 2024 3:05pm

BMS axes Eisai ADC pact 3 years after paying $650M

Jul 1, 2024 9:00am